Anavex Life Sciences Corp. (AVXL)
| Market Cap | 277.09M -65.9% |
| Revenue (ttm) | n/a |
| Net Income | -13.02M |
| EPS | -0.14 |
| Shares Out | 92.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 893,386 |
| Open | 3.120 |
| Previous Close | 3.130 |
| Day's Range | 2.960 - 3.130 |
| 52-Week Range | 2.255 - 10.400 |
| Beta | 1.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 25, 2026 |
About AVXL
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ... [Read more]
Financial Performance
Financial StatementsNews
Anavex Life Sciences Quarterly report: Q2 2026
Anavex Life Sciences has published its Q2 2026 quarterly earnings report on September 1, 2026.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 27, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
Clinical Development Strategy for Alzheimer's Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer's Disease Clinical Study Dat...
Anavex Life Sciences Earnings release: Q3 2026
Anavex Life Sciences released its Q3 2026 earnings on August 25, 2026, summarizing the period's financial results.
Anavex Life Sciences Quarterly report: Q3 2026
Anavex Life Sciences has published its Q3 2026 quarterly earnings report on August 25, 2026.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
Launches VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees and How to Vote at the Annual Meeting of Stockholders
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 17, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 17, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 11, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 11, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments fo...
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on July 24, 2026, providing details for shareholder voting and corporate governance matters.
Anavex receives expected Nasdaq delinquency notification
Anavex (AVXL) Life Sciences announced it received an expected delinquency notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on May 20, 2026. The Notice indicate...
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments...
Anavex delays 10Q filing
The company states: “Anavex (AVXL) Life Sciences is unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 by the prescribed May…
Anavex Life Sciences names Terrie Kellmeyer interim CEO, succeeding Missling
Anavex (AVXL) Life Sciences announced that its board has appointed former senior VP of clinical development and current senior advisor Terrie Kellmeyer as interim CEO. The appointment follows the depa...
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments...
Anavex initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Anavex (AVXL) with a Buy rating and $20 price target implying 500% upside from the current share price. The company is developing oral therapies…
Anavex Life Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The session highlighted strong phase IIb/III results for blarcamesine in Alzheimer's, with significant cognitive and biomarker benefits, a robust safety profile, and a focus on pivotal studies for regulatory approval. Expansion into Parkinson's and rare diseases is supported by mechanistic rationale and financial stability.
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease
Findings underpin the scientific rationale for Anavex's targeted autophagy approach with orally administered blarcamesine
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex gives update after blarcamesine marketing authorization withdrawal
Anavex (AVXL) provided a regulatory update. Following the withdrawal of the application for the marketing authorization of blarcamesine in the EU, Anavex will continue to gather additional data and co...